CCO Oncology Podcast

Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL

Episode Summary

Listen to Jeremy S. Abramson, MD, MMSc, discuss the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.

Episode Notes

In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:

• Approved and Investigational Targeted Therapeutics for CLL  
• Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell Lymphoma
• Bispecific Antibodies and Other Investigational Targeted Agents for Lymphomas
• Treatment for Older Patients With Hodgkin Lymphoma

Presenters:

Jeremy S. Abramson, MD, MMSc
Associate Professor  
Department of Medicine  
Harvard Medical School  
Director, Center for Lymphoma  
Massachusetts General Hospital  
Boston, Massachusetts

Content based on an online CME program supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology.

Link to full program:
https://bit.ly/3tyQ9nG